title: Herpes simplex virus-mediated activation of human immunodeficiency virus is inhibited by oligonucleoside methylphosphonates that target immediate-early mRNAs 1 and 3.
abstract: IE1 and IE3 mRNAs and their protein products (IE110 and IE175, respectively) were detected in HSV-1-infected U937 cells at 4-15 hours postinfection. In transient expression assays with infectious HIV or an HIV-LTR-directed chloramphenicol acetyltransferase construction (HIV-LTRcat), HSV-1 caused HIV activation (86.7% +/- 6.4% conversion). Electrophoretic mobility shift assays with DNA sequences that encompass the LBP-1 binding site revealed increased levels of DNA-protein complex formation with nuclear extracts from HSV-1 infected as compared with uninfected U937 cells. Novel bands were not seen. HSV-1 mutants respectively deleted in IE110 (dl1403) or IE175 (d120) activated HIV as well as wild-type virus. However, HSV-1-mediated activation was inhibited (26% conversion) by simultaneous treatment with oligonucleoside methylphosphonates (ONMP) that specifically inhibit expression of IE110 (IE1TI) or IE175 (IE3TI). ONMP did not inhibit activation when used individually (83.8% and 67.8% conversion with IETI1 and IE3TI, respectively). Combinations of mutant ONMP that do not inhibit IE110 or IE175 expression did not reduce the levels of HSV-1-mediated activation. These findings suggest that HSV genes IE1 and IE3 can independently activate HIV in monocytic cells and ONMP that target HSV IE genes can be used to inhibit HIV activation.
authors.affiliation: Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201-1192, USA.
authors.forename: C P
authors.initials: CP
authors.lastname: Feng
authors.forename: M
authors.initials: M
authors.lastname: Kulka
authors.forename: C
authors.initials: C
authors.lastname: Smith
authors.forename: L
authors.initials: L
authors.lastname: Aurelian
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D002460:Cell Line; D015500:Chloramphenicol O-Acetyltransferase / Q000096:biosynthesis; D019084:Fluorescent Antibody Technique, Indirect; D017930:Genes, Reporter; D006678:HIV / Q000187:drug effects / Q000235:genetics / Q000254:growth & development*; D016325:HIV Long Terminal Repeat; D018259:Herpesvirus 1, Human / Q000502:physiology*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D009943:Organophosphorus Compounds; D012333:RNA, Messenger / Q000096:biosynthesis*; D012367:RNA, Viral / Q000096:biosynthesis; D014162:Transfection; D014407:Tumor Cells, Cultured; D014775:Virus Activation / Q000187:drug effects* / Q000502:physiology
chemical_list: D000998:Antiviral Agents; D016376:Oligonucleotides, Antisense; D009943:Organophosphorus Compounds; D012333:RNA, Messenger; D012367:RNA, Viral; C032627:methylphosphonic acid; D015500:Chloramphenicol O-Acetyltransferase